Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment
Acta Neurobiologiae Experimentalis · 2023
DOI: 10.55782/ane-2023-008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neurobiologiae Experimentalis, 2023. Verfasst von Majid Motaghinejad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti Universi…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Methylphenidate, Neuroprotective Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The potential of minocycline to protect against methylphenidate‑induced neurodegeneration has been extensively reported in the literature but the mechanism of action is still unknown. This study aims to determine the role of mitochondrial chain enzymes and redox homeostasis on the neuroprotective effects of minocycline in methylphenidate‑induced neurodegeneration. Wistar adult male rats were randomly assigned to the seven experimental groups: Group 1 received saline solution; Group 2 received methylphenidate (10 mg/kg, i.p.); Groups 3, 4, 5, and 6 received methylphenidate and minocycline for 21 days; Group 7 received minocycline alone. Cognition was evaluated with the Morris water maze test. Activity of the hippocampal mitochondrial quadruple complexes I, II, III and IV, mitochondrial membrane potential, adenosine triphosphate (ATP) levels, total antioxidant capacity, and reactive oxygen species were determined. Treatment with minocycline inhibited methylphenidate‑induced cognitive dysfunction. Minocycline treatment increased mitochondrial quadruple complex activities, mitochondrial membrane potential, total antioxidant capacity, and ATP levels in the dentate gyrus and cornu ammonis‑1 (CA1) areas of the hippocampus. Minocycline is likely to confer neuroprotection against methylphenidate‑induced neurodegeneration and cognition impairment by regulating mitochondrial activity and oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, dr.motaghinejad6@gmail.com.
- Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University, Durham, NC, USA.
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, Turkey.
Zitieren
APA
Motaghinejad, M., Motevalian, M., Ulloa, L., Kaviani, N., & Hamurtekin, E. (2023). Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment. Acta Neurobiologiae Experimentalis. https://doi.org/10.55782/ane-2023-008
Vancouver
Motaghinejad M, Motevalian M, Ulloa L, Kaviani N, Hamurtekin E. Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment. Acta Neurobiologiae Experimentalis. 2023. doi:10.55782/ane-2023-008
BibTeX
@article{Motaghinejad2023,
author = {Motaghinejad, Majid and Motevalian, Manijeh and Ulloa, Luis and Kaviani, Neda and Hamurtekin, Emre},
title = {Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment},
journal = {Acta Neurobiologiae Experimentalis},
year = {2023},
doi = {10.55782/ane-2023-008}
}
EUVIMED